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Abstract
The spf/ashmouse model of ornithine transcarbamylase (OTC) deficiency, a severe urea
cycle disorder, is caused by a mutation (c.386G>A; p.R129H) in the last nucleotide of exon
4 of the Otc gene, affecting the 5’ splice site and resulting in partial use of a cryptic splice
site 48 bp into the adjacent intron. The equivalent nucleotide change and predicted amino
acid change is found in OTC deficient patients. Here we have used liver tissue and mini-
gene assays to dissect the transcriptional profile resulting from the “spf/ash”mutation in
mice and man. For the mutant mouse, we confirmed liver transcripts corresponding to par-
tial intron 4 retention by the use of the c.386+48 cryptic site and to normally spliced tran-
scripts, with exon 4 always containing the c.386G>A (p.R129H) variant. In contrast, the
OTC patient exhibited exon 4 skipping or c.386G>A (p.R129H)-variant exon 4 retention by
using the natural or a cryptic splice site at nucleotide position c.386+4. The corresponding
OTC tissue enzyme activities were between 3-6% of normal control in mouse and human
liver. The use of the cryptic splice sites was reproduced in minigenes carrying murine or
human mutant sequences. Some normally spliced transcripts could be detected in mini-
genes in both cases. Antisense oligonucleotides designed to block the murine cryptic +48
site were used in minigenes in an attempt to redirect splicing to the natural site. The results
highlight the relevance of in depth investigations of the molecular mechanisms of splicing
mutations and potential therapeutic approaches. Notably, they emphasize the fact that find-
ings in animal models may not be applicable for human patients due to the different genomic
context of the mutations.
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Introduction
Ornithine transcarbamylase (OTC) deficiency (OMIM 311250) is the most frequent defect
among disorders of the urea cycle, the metabolic pathway that removes waste nitrogen from
the body. In the liver, OTC is located in mitochondria of periportal hepatocytes and catalyses
the condensation of carbamyl phosphate with ornithine for the formation of citrulline. Since
OTC deficiency is X-linked, hemizygous males generally exhibit severe symptoms in the neo-
natal period while heterozygous females show variable phenotypes depending on the pattern of
X inactivation in hepatocytes. However, phenotypic heterogeneity is also observed in males
correlating with the severity of the mutations and possibly other genetic and environmental
factors [1,2,3].
As in other urea cycle disorders, OTC deficiency presents with hyperammonemia and dif-
ferential diagnosis is based on a characteristic plasma amino acid profile (elevated glutamine
and absent or decreased citrulline and arginine), presence of elevated urine orotic acid and ura-
cil and on the genetic analysis of the OTC gene. Patients are at risk of potentially fatal acute
hyperammonemia and clinical symptoms are mainly caused by the toxic effects of ammonia in
brain, including lethargy, seizures, neurological impairment, brain edema and coma [4]. Stan-
dard treatment is based on dietary protein restriction to decrease nitrogen load, use of nitrogen
scavengers such as sodium phenylbutyrate and sodium benzoate and provision of an adequate
supply of citrulline and arginine. In patients with severe forms, liver transplantation has been
proven effective for preventing further hyperammonemic crises [3,4].
To date, more than 440 mutations have been described in the OTC gene (HGMD Profes-
sional Release 2014.1) and include a majority of missense mutations as well as splicing defects,
small deletions or insertions and large deletions [5,6]. However, a high proportion (15%) of pa-
tients with a biochemical diagnosis of OTC deficiency do not carry a mutation in the OTC gene
identifiable by conventional methods [5,7], suggesting that the remaining alleles may corre-
spond to mutations localized in the promoter or deep intronic regions, or are due to locus het-
erogeneity [8].
Two mouse models currently exist for OTC deficiency, which are useful for ongoing and fu-
ture research in therapeutical approaches for the management of the disease. The sparse fur
(spf) mouse carries a missense change (p.H117N) that results in partial (10%) OTC liver activi-
ty [9], while the spf/ash (abnormal skin and hair) mouse model carries a point mutation
(c.386G>A) located in the last nucleotide of exon 4 resulting in the missense change p.R129H,
that does not impair enzymatic activity [10]. However, transcript analysis in the spf/ashmouse
liver revealed the presence of greatly reduced OtcmRNA levels (10%) corresponding to a nor-
mally spliced product (transcript with the missense p.R129H change) and another product re-
sulting from the use of a cryptic splice site at c.386+48, giving rise to an elongated protein (16
amino acids extra) which is degraded rapidly and is inactive [10]. Presumably, the 90% de-
crease in transcripts detected as OtcmRNA results from other aberrant splicing events possibly
causing a frameshift and a premature termination codon and are degraded by the nonsense
mediated decay (NMD) mechanism. Overall, hepatic OTC activity in the spf/ashmouse was re-
ported by several authors to be 5–10% of wild-type levels [11,12,13], which is attributed to the
normally spliced allele with the p.R129H change. This confers a mild phenotype with elevated
urinary orotic acid levels but no clinically significant hyperammonemia [10].
Interestingly, several OTC deficient patients carrying the corresponding nucleotide change,
c.386G>A have been identified (Table 1). The mutation lies in a CpG dinucleotide explaining
the recurrence. As shown in Table 1, the “spf/ash” mutation is present in males as well as in
asymptomatic and manifesting female patients and is associated both with early and with late
onset of the disease. In two Spanish families carrying the mutation, two of the male patients
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and a clinically manifesting female had normal physical and mental development [14]. OTC
activity in jejunal biopsies from female and male patients with this mutation was very low but
detectable (1.3–3.5% relative to control values) [14].
Among the RNA targeting therapies for splicing mutations, one of the most promising ex-
perimental approaches today is the use of antisense oligonucleotides (AONs) that act by steri-
cally blocking the access of the spliceosomal components to targeted pre-mRNA regions
[15,16]. AONs have been used to prevent intronic pseudoexon inclusion, block cryptic splice
sites, induce exon skipping to overcome nonsense or frameshift mutations, promote therapeu-
tically relevant exon inclusion or generation of specific isoforms [17]. The use of AON to block
cryptic splice sites activated by mutations can provide a therapeutic approach to recover nor-
mal splicing and functional protein. In this sense, the spf/ashmouse could represent a natural
animal model in which to test antisense therapy for a liver enzyme, taking into account that the
missense mutation (p.R129H) resulting from correctly spliced mRNA does not affect mito-
chondrial import, subunit assembly or enzymatic activity of the OTC enzyme [10]. As men-
tioned above, human patients carrying the same nucleotide change have been identified.
However, although the Otc coding sequence has 92% identity to the human sequence, intronic
sequences vary to a great extent. In this work, we sought to study the molecular mechanism of
the pathogenic nature of the c.386A>Gmutation in mice and man, analyzing human and mu-
rine liver samples and minigenes. In addition we have investigated the therapeutic potential of
AONs designed to block cryptic splice sites.
Materials and Methods
RT-PCR analysis in liver samples
Mouse liver samples (wild-type and spf/ash) were obtained in accordance with the guidelines
and policies of the Veterinary Office of the State of Zurich and Swiss law on animal protection,
the Swiss Federal Act on Animal Protection (1978), and the Swiss Animal Protection
Table 1. OTC deficient patients with the c.386G>Amutation.
No. of
patients
Sex Onset Phenotype and outcome Reference
1 female late mild hyperammonemia psychiatric symptoms [39]
1 male early n.d.a. [40]
6 5 males, 1 female early/late 3 died, 3 with recurrent crises & normal development [14]
5 n.d.a. n.d.a. n.d.a. [41]
1 male neonatal n.d.a. [42]
at least 2 1 female/ male (no number
given)
”manifesting female”/
late
n.d.a. [2]
1 female late mild hyperammonemia normal neurology [43]
1 male late no hyperammonemia vomiting and confusion leading to
diagnosis
this work*
1 male neonatal mild course, no recurrent hyperammonemia this work*
2 females asymptomaticmothers normal this work*
1# male neonatal recurrent severe hyperammonemia, neurodevelopmental
delay
this work*
n.d.a. no data available
* patients referred to and genotyped at University Children’s Hospital, Zürich.
# Liver tissue from this patient obtained after liver transplantation was used for transcript and enzyme analysis in the present study.
doi:10.1371/journal.pone.0122966.t001
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Ordinance (1981). Animal studies received approval from by the Cantonal Veterinary Office,
Zurich, and the Cantonal Committee for Animal Experiments, Zurich, Switzerland (permis-
sion for animal experiments Kt ZH130-2014). For this study we used frozen liver samples ob-
tained in a previous study and no animals were specifically sacrificed.
Human liver sample was obtained from a male OTC patient (listed in Table 1) undergoing
liver transplantation. Ethical approval for the use of human samples in the study was granted
by the Institutional Ethics Committee (reference KEK-ZH-Nr. 2014–0628).
For in vivo studies with wild-type or spf/ashmice, total RNA was isolated from 20 to 30 mg
of mouse liver tissue using QIAmp RNA blood mini kit (Qiagen) according to the manufactur-
er’s protocol. Random primed cDNA was prepared from 1 μg of total RNA using the Reverse
Transcription kit (Promega). PCR amplification of the region from exon 1 to exon 10 of the
Otc-mRNA was performed using the following primers: forward primer 5’-ATGCTGTC-
TAATTTGAGGATCCTGC-3’ and reverse primer 5’-AGCACAGGTGAGTAGTCTGT-
CAGCA-3’. PCR for 40 cycles using PfuUtral II Fusion HS DNA polymerase (Agilent
Technologies) was performed at an annealing temperature of 50°C. Amplified products were
separated by agarose gel electrophoresis and the products were analyzed by direct sequencing
with the same forward and reverse primers after extraction with NucleoSpin Gel and PCR
clean-up (Macherey-Nagel).
Human liver samples were immediately stored after biopsies at a temperature of -80°C and
investigated using a published protocol with slight modifications [8]. In brief, tissue was dis-
rupted and homogenized using the QIAgen TissueRuptor (QIAGEN GmbH). Extraction of
total RNA was performed according to the QIAGEN RNeasy Kit (QIAGEN). Hence, 1 μg of
total RNA was used for cDNA synthesis in the presence of PrimeScript II RTase (Takara Clon-
tech). cDNA was amplified with the following primers, generating two overlapping OTC frag-
ments: fragment 1 forward primer: 5’GAAGATGCTGTTTAATCTGAGG, reverse primer:
5’CTGGAGCGTGAGGTAATCAGCC (expected size 580 bp); fragment 2 forward primer:
5’GCAGATGCAGTATTGGCTCG, reverse primer: 5’CCCATACCACGTGTTAGGGATT
(expected size 814 bp). In the patient and wild-type control, a full length amplification of the
transcript was performed using the forward primer of fragment 1 and the reverse primer of
fragment 2 (expected size 1220 bp). For the purpose of sequencing all primers contained
M13-tags. PCRs were performed at an annealing temperature of 60 °C.
OTC activity
OTC activity was determined from mouse and human liver samples in triplicates, following es-
tablished procedures [18].
Minigenes
For evaluation of in vitro splicing using minigenes, PCR-amplified genomic fragments includ-
ing OTC exon 4 and flanking intronic sequences from human (control fibroblasts) or mouse
(C57/BL6) were cloned in the pSPL3 vector (Exon Trapping System, Gibco, BRL). Control fi-
broblasts were obtained from Coriell Cell Repositories (NJ, USA) and mouse samples from the
Animal Core facility at the Centro de Biología Molecular Severo Ochoa. No mice were sacri-
ficed specifically for this study. Ethical approval for the use of human and mouse samples in
the study was granted by the institutional Ethics Committee (Universidad Autónoma de
Madrid).
The mutations were introduced by site-directed mutagenesis with the Quikchange II site-di-
rected mutagenesis kit (Agilent Technologies). For the minigene assay, 3105 Hep3B cells
grown in 6-well plates were transfected with a total of 1.5 μg of wild-type or mutant minigenes
OTC spf/ash Splicing Mutation in Mice and Man
PLOSONE | DOI:10.1371/journal.pone.0122966 April 8, 2015 4 / 13
using JetPEI (Polyplus Transfection). At 24h post-transfection, cells were harvested and total
RNA purified using Trizol reagent (Invitrogen). RT-PCR was performed with Superscript III
First-Strand Synthesis System and FastStart Taq DNA Polymerase (Roche Applied Science)
using vector specific primers SD6 and SA2. To select transcripts resulting from the use of the
natural 5’ splice site (5’ss) or the cryptic c.386+4 splice site, specific forward primers were de-
signed hybridizing with exon 4 or exon 4 plus the first four intronic nucleotides and exonic vec-
tor sequences, respectively (NAT: 5’-ACACCGCTCGACCTGGAGATC-3’ and CRYP: 5’-
CGCTCGGTTTACCTGGAGATC-3’). Both primers hybridize with murine and human se-
quences. In all cases, SA2 was used as antisense primer. Amplified products were separated by
agarose gel electrophoresis and the excised bands analyzed by direct sequencing after extrac-
tion with QIAEX II Gel Extraction kit (Qiagen). All the experiments were reproduced at least
three times.
In silico analysis
To investigate the effect of the c.386G>Amutation on the splice site strength of mouse and
human OTC exon 4 and the presence of potential cryptic splice sites nearby, we have per-
formed in silico analysis using different softwares: Berkeley Drosophila Genome Project Splice
Site Prediction (BDGP, http://www.fruitfly.org/seq_tools/splice.html), Analyzer Splice Tool
(AST; http://ibis.tau.ac.il/ssat/SpliceSiteFrame.htm), Maximum Entropy Modelling (MaxEnt;
http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) and Human Splicing
Finder (HSF, http://www.umd.be/HSF/).
Antisense oligonucleotides
A 25-mer morpholino AON designed against murine c.386+48 cryptic splice site was provided
by Gene Tools (5’- ATCTTCTCTTTTAAACTAACCCATC-3’). An oligonucleotide hybridiz-
ing to an intronic region in an unrelated gene was used as negative control. Hep3B cells were
transfected with wild-type or mutant minigenes as described above and 24 h later different
concentrations of AON (10–30 μM) were transfected using Endoporter (Gene Tools). Cells
were harvested after another 24 h, RNA isolated and RT-PCR analysis performed as described
above. The experiments were reproduced at least three times.
Results
Effect on splicing of the spf/ash mutation in mouse and human
The effect of the c.386G>A mutation on OTC exon 4 splicing was analysed in liver samples
from spf/ashmice and from a male patient with the equivalent variation. RT-PCR analysis and
subsequent DNA sequencing confirmed a splicing defect in both samples (Fig 1 and S1 Fig).
For the mutant mouse, the analysis confirmed previously published results [10] as we detected
transcripts corresponding to partial intron 4 retention by the use of the c.386+48 cryptic splice
site as well as normally spliced transcripts, always containing the c.386G>A (p.R129H) variant.
In contrast, in the OTC patient we observed exon 4 skipping or variant (c.386G>A; p.R129H)
exon 4 retention by using the natural or a cryptic splice site at nucleotide position c.386+4. The
corresponding OTC enzyme activities in liver were 5.6% of normal control (7,2 versus
127,3 μmol/mg/hr) in mouse and 3.7% (0.4 versus 10,9 μmol/mg/hr) in human tissues.
The transcript profile in wild-type and mutant murine and human exon 4 sequences was
also analysed in vitro using minigenes. As shown in Fig 2, the wild-type murine minigene pro-
duced two transcripts both with the correct inclusion of exon 4 and corresponding to either the
use of or no use of a cryptic acceptor splice site in the vector. The mutant murine minigene
OTC spf/ash Splicing Mutation in Mice and Man
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resulted in several aberrant transcripts corresponding to the use of the c.386+48 cryptic splice
site, exon skipping and/or retention of entire intron 4. A faint band corresponding in size to
the use of the mutant 5’ ss (along with the use of the vector cryptic acceptor splice site) could
be detected but its low abundance precluded sequence analysis. In contrast, the mutant human
minigene produced only one aberrant transcript corresponding to inclusion of exon 4 plus four
adjacent intronic nucleotides that resulted from the use of the c.386+4 cryptic splice site. In the
human minigene only the cryptic acceptor site in the vector was used in the splicing process.
Analyzing with different splice prediction programs the murine and human OTC exon 4 se-
quences in its wild-type or mutant (c.386G>A) versions indicated that the natural 5’ splice site
lacks a strong splice score, and is not even recognized by the BDGP software (Table 2). The spf/
ashmutation further decreases the splicing score in both human and murine sequences. In
Fig 1. RT-PCR analysis in liver samples from spf/ashmouse and from an OTCD patient carrying the analogous c.386G>Amutation. The figure
shows the result of amplifying the full length cDNA transcript in mice and a fragment encompassing exons 1 to 5 for the human samples. The schematic
drawings on both sides show the identity of the bands which were characterized by sequence analysis (see S1 Fig). The faint bands in the mouse samples
could not be sequenced. The star indicates the presence of the c.386G>Amutation. Numbers indicate the position of the cryptic splice sites used.
doi:10.1371/journal.pone.0122966.g001
Fig 2. Minigene analysis of the c.386G>A (spf/ash) mutation in the murineOtc and humanOTC genes. The gel shows the RT-PCR analysis in Hep3B
cells transfected with the wild-type and mutant minigenes carrying the mouse and human genomic sequences (exon 4 and flanking intronic sequences). The
schematic drawings on both sides show the identity of the bands which were characterized by sequence analysis. Grey boxes represent vector sequences
(V) and white boxes exon 4. The star indicates the presence of the c.386G>Amutation. Numbers indicate the position of the cryptic splice sites used. The
box denoted as cV indicates a stretch of vector sequence that is retained in the mRNA due to the use of a cryptic splice acceptor site.
doi:10.1371/journal.pone.0122966.g002
OTC spf/ash Splicing Mutation in Mice and Man
PLOSONE | DOI:10.1371/journal.pone.0122966 April 8, 2015 6 / 13
mouse, the cryptic c.386+48 site has a predicted higher splice site strength compared to the nat-
ural site. The cryptic splice site c.386+4 is present on both human and murine sequences and
has a score comparable to or slightly higher than the mutated 5’ ss, depending on the program
used (Table 2).
In the spf/ashmouse and in human liver samples, some normally spliced transcripts (with
the c.386G>A change) were detected (Fig 1), so we sought to confirm this in minigenes using a
forward primer hybridizing to the junction of exon 4 and the vector exonic sequence (Fig 3A,
NAT primer). In addition, the use of the c.386+4 cryptic splice site was also investigated using
another specific primer that included the first four nucleotides of intron 4 (Fig 3A, CRYP prim-
er). The normally spliced transcript could be amplified in all cases, although the amount was
much lower with the mutant murine minigenes (Fig 3B). This was confirmed by semiquantita-
tive PCR analysis (<30 cyles) (S2 Fig). The results confirm that some amount of normally
spliced transcript is produced contributing to the mild phenotype observed in the mouse
model and in patients with the mutation. Using the CRYP primer specific for the use of the
cryptic c.386+4 splice site, we could also obtain amplified product in wild-type and mutant
context, in both the human and murine minigenes, indicating this alternative splice site to be
potentially active.
Using AONs to block the cryptic splice sites activated by the c.386G>A
mutation
In the human sequences, the cryptic splice site used (c.386+4) is included in the natural 5’ ss
and is involved in base-pair interaction with U1snRNA, thus precluding the possibility of steri-
cally blocking it by AONs. However, in the murine sequences, the antisense approach is feasi-
ble for the cryptic c.386+48 site. Having in mind that a mouse model for preclinical
development of antisense therapy in metabolic diseases would be highly useful, we investigated
the possibility of redirecting transcript processing by a specific splice blocking AON targeted to
the c.386+48 cryptic splice site. For this purpose we treated Hep3B cells, previously transfected
with wild-type or mutant murine minigenes, with 10–30 μM of AON and analyzed the
transcriptional profile.
Table 2. In silico analysis ofOTC exon 4 splice sites (ss), including wild-type andmutant (c.386G>A) sequences and cryptic splice sites.
MaxEnt BDGP AST HSF
Exon 4 OTC gene (human)
3’ss tttttttattgtag/G 10,3 1 93,6 87,0
Wild-type 5’ss CCG/gtttgt 4,8 0 70,6 81,4
Mutant 5’ss CCA/gtttgt -1,5 0 58,7 70,8
Cryptic 5’ss (+4) TTT/gtaaat -2,3 0 63,0 70,2
5’ss (+48)* TGG/ataaat - -. - -.
Exon 4 Otc gene (mouse)
3’ ss ttcttttgttctag/G 11,8 1 94,41 86,3
Wild-type 5’ss TCG/gtttgt 3,5 0 66,6 79,4
Mutant 5’ss TCA/gtttgt -3,7 0 54,7 68,8
Cryptic 5’ss (+4) TTT/gtaaaa -6,6 0 57,7 67,9
Cryptic 5’ss (+48) TGG/gttagt 3,1 0,8 76,6 88,1
Higher positive scores indicate a predicted better splice site. The 3’ and 5’ splice acceptor sites are shown, exonic sequences in upper case, intronic
sequences in lower case.
* not a cryptic splice site; sequence corresponding to that shown for the cryptic 5’ ss (+48) of the mouse
doi:10.1371/journal.pone.0122966.t002
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As can be seen in Fig 4, in the presence of AON the band corresponding to the insertion of
48 intronic nucleotides disappeared indicating that the AON efficiently and specifically blocks
the use of the cryptic splice site. No effect was visible using a scrambled oligo. Concomitantly,
an increase in the band corresponding to intron 4 retention was detected. We did not observe
an increase in the band which corresponds by size to the use of the natural splice site or the
cryptic c.386+4 site. To corroborate this, we used specific primers NAT and CRYP (Fig 3). As
can be seen in Fig 3B, AON treatment did not result in any detectable increase of these specific
amplified products.
Fig 3. Minigene analysis with specific primers for the natural or cryptic c.386+4 splice sites. A) Schematic drawing of the location of the primers, the
murine and human cryptic splice sites and the sequence targeted by the AON. The star indicates the presence of the c.386G>Amutation. cVss: cryptic
vector acceptor splice site. B) RT-PCR analysis using the denoted primer pairs obtained for murine wild-type (wt) or mutant (mut) minigenes cotransfected or
not with a specific AON targeting the cryptic c.386+48 splice site. C) RT-PCR analysis using the denoted primer pairs obtained in Hep3B cells transfected
with human wild-type or mutant minigenes. Sequencing analysis confirmed the identity of the bands and the use of the specific splice site in each case.
doi:10.1371/journal.pone.0122966.g003
OTC spf/ash Splicing Mutation in Mice and Man
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Discussion
Splicing defects are estimated to represent up to one third of the disease causing mutations in
human genes [19]. Among them, mutations located within the 5’ss are the most common, es-
pecially those affecting the invariant GU residues at positions +1 and +2 [20]. Exonic variations
even within the 5’ ss are usually interpreted on the basis of the genetic code and without the di-
rect analysis of the patient’s RNA are often not considered to affect splicing. However, in recent
years it has become clear that any mutation in the coding sequence may affect pre-mRNA
splicing and thus it has been suggested that the “splicing code” overrules the predictions based
on the genetic code [21].
In this work we have characterized the c.386G>A change in the Otc gene identified initially
to be the disease causing mutation in the spf/ashmouse model of OTC deficiency and subse-
quently found in several OTC deficient patients. The mutation is located on the last nucleotide
of exon 4 and was classified initially as missense (p.R129H) [22] although subsequent analysis
of Otc transcripts in the mouse liver revealed that it partially affected the splicing process [10].
Now we have reevaluated the in vivo effect on splicing of this change both in murine spf/ash
and in human OTCD liver samples as well as used in vitro experimental approaches based
on minigenes.
Exon 4 of the OTC gene can be considered a weakly defined exon as its 5’ ss scores low in all
splice prediction programs. This means it has more mismatches to the consensus sequence and
thus will not be recognized very efficiently by spliceosomal components such as snRNA U1
that binds by base-pair complementarity initiating the splicing process. Based on this in silico
evaluation it can be hypothesized that exon 4 may be a vulnerable exon prone to splicing de-
fects, which is corroborated by the fact that the c.386G>Amutation caused aberrant splicing
in the mouse [10]. Two other mutations affecting the same nucleotide, c.386G>T and
c.386G>C, have also been identified in human patients [5]. Both are assumed to affect the
splicing process on the basis of their location and the results obtained in the spf/ashmouse. In
this work we assess the splicing defect of the spf/ashmutation in liver from human patients and
establish a minigene assay for human and murine exon 4 sequences to reproduce the results
Fig 4. Effect of AON targeting the c.386G>A cryptic splice site on the splicing profile of murine minigenes.Wild-type (wt) and mutant (mut) murine
minigenes transfected in Hep3B cells were cotransfected with 20 μM of AON and RT-PCR analysis performed after 24 h. SCR, scrambled oligonucleotide.
The schematic drawings on both sides show the identity of the bands which were characterized by sequence analysis. Grey boxes represent vector
sequences (V) and white boxes indicate exon 4. Numbers indicate the position of the cryptic splice sites used. The box denoted as cV indicates a stretch of
vector DNA that is retained in the mRNA due to the use of a vector cryptic splice site. The star indicates the presence of the c.386G>Amutation. The arrow
points to the band corresponding to the use of the cryptic c.386+48 site in the mutant minigenes.
doi:10.1371/journal.pone.0122966.g004
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and to serve as assay system to test antisense therapeutic approaches. The splicing pattern ob-
served for mutant minigenes mirrored the one in vivo relative to the use of cryptic splice sites
(c.386+4 in human sequences and c.386+48 in murine sequences). However, exon 4 skipping
was observed in vivo in human liver while this event was not detected in mouse liver, being de-
tected only for mutant murine minigenes. In this respect, it was shown that the splicing out-
come of mutated NF1 exons 36 and 37 in minigenes depends on the genomic context cloned,
indicating that exon definition relies not only in the characteristics of the exons themselves but
on the wider genomic environment within which they are located [23]. This also applies to the
observed intron 4 retention in mutant mouse minigenes, which may be an artifact related to
the short genomic sequence cloned (mouse Otc intron 4 is 23,5 Kb long).
The in vivo and in vitro results correlated well with in silico analysis predicting the presence
of cryptic splice sites in mouse and human sequences. Previous evidences may aid in under-
standing the differences observed. In this respect, Roca et al. identified pairwise dependencies
between 5’ splice site nucleotides that determine the splicing efficiency [24]. Comparing mouse
and human cryptic +4 sites, there is one mismatch difference in mouse (only 4 complementary
nucleotides to U1) so a decreased use of the +4 site in mouse compared to humans is expected.
The comparison of the results obtained with murine and human minigenes highlights the fact
that identical mutations can have a different effect due to the neighboring sequence context,
thus making necessary to characterize functionally each change with appropriate experimental
approaches. Possibly, inter-species differences in the intronic nucleotides defining auxiliary
splicing signals along with local RNA secondary structures and other factors that may affect
RNA splicing act together to produce the final splicing profile in each case, as previously dis-
cussed [20]. As mentioned before, in vivo there may be differences compared to minigenes in
the resultant splicing profiles due to the wider natural genomic context. However, in vitro anal-
ysis in minigenes generally provides an accurate view of the effect of mutations on the splicing
process [25,26], extremely useful when transcriptional analysis is not possible.
Based on our previous work on antisense therapy for splicing defects [27], [28] one of our
aims was to investigate the feasibility of correcting the spf/ashmutation and rescuing OTC expres-
sion by the use of AONs. The development of oligonucleotide therapeutics is progressing rapidly,
with a large number of disease targets residing in the liver [29]. Antisense therapy with splice
switching AONs has several advantages which include the fact that the corrected mRNA is tran-
scribed in its natural context and under its native control and that it is easier to implement than
gene therapy. Our hypothesis was that blocking the cryptic splice sites could restore splicing at the
natural (albeit mutated) splice site, so a functional protein would be produced, as the missense
change p.R129H does not impair enzyme function [10]. However, this was only possible for the
murine sequences as in humans the cryptic splice site used is included in the natural splice site.
The results obtained with an AON blocking the c.386G>A indicate that normal splicing
cannot be rescued, as other aberrant splicing events are favored. This can be explained by the
fact that the mutated splice site has a suboptimal splice score as a consequence of the spf/ash
mutation. When AONs have been used to block cryptic splice sites, natural splice sites were in-
tact [30], which may be a prerequisite in most cases. Other therapeutic approaches should be
investigated in this case, such as the use of adapted U1 snRNA that may compensate for the
mutation in the 5’ splice site [31] and drugs that modulate splicing [32,33].
The elucidation of the precise molecular mechanism of the spf/ashmutation in mice and
man as described in this work offers relevant data for the establishment of genotype-phenotype
correlations in OTC deficiency. In the field of splicing defects the relationship between geno-
type and phenotype is often elusive due to lack of experimental evidence of the molecular
mechanism of the mutations. In general, splicing mutations are primarily associated with com-
plete lack of function and severe effects, especially mutations affecting conserved nucleotides
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GU and AG at 5’ and 3’ ss, respectively. However there are notable exceptions as some muta-
tions affecting nucleotide +1 have been shown to account for a functional protein variant due
to activation of a cryptic splice site [34,35]. In addition, many splicing mutations are “leaky” re-
sulting in partial correct splicing that accounts for milder phenotypes [36,37]. Patients with the
spf/ashmutation retain some residual activity, and can have mild or even no hyperammonemia
and normal development (Table 1), indicating a milder effect of the mutation in some patients.
In agreement with this, the spf/ashmouse also exhibits a milder phenotype [10]. In humans,
use of the c.386+4 cryptic splice site would result in an out-of-frame transcript. In mice, the use
of the c.386+48 site results in a non-functional elongated protein [10]. Exon skipping would re-
sult in an out of frame transcript. The presence of correctly spliced OTC transcripts (coding for
the p.R129H variant) was observed in vitro and in vivo providing an explanation for the not al-
ways severe phenotype in mice and man. Interindividual differences in the expression of splic-
ing factors may influence the relative abundance of correctly spliced and aberrant transcripts
leading to phenotypic variability observed (Table 1), as has been discussed in other cases for
patients with the same genotype [38].
In conclusion, the detailed analysis of the spf/ashmutation molecular pathology has allowed
establishing the relationship to the phenotype and the investigation of potential targeted thera-
pies. The minigene system may be used to evaluate other point mutations in exon 4 which
may affect the splicing process, taking into account that exon 4 may be vulnerable to splicing
defects.
Supporting Information
S1 Fig. Sequence analysis of the amplified products obtained after RT-PCR frommurine
and human liver samples. The chromatograms show the sequencing results of the bands
shown in Fig 1 corresponding to RT-PCR analysis form wild-type mouse samples (A), spf/ash
mouse samples (B), wild type human liver (C) and liver samples from the OTCD patient,
upper band (D) and lower band (E).
(PDF)
S2 Fig. Semiquantitative RT-PCR analysis in minigenes using specific primers for the natu-
ral or cryptic c.386+4 splice sites. The gel shows the results of RT-PCR analysis (limiting the
number of cycles in the PCR to 30) obtained for murine wild-type (wt) or mutant (mut) mini-
genes cotransfected or not with a specific AON targeting the cryptic c.386+48 splice site, as
shown in Fig 3.
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